Development of genomic markers that predict response to molecularly targeted antileukemic therapy.
The cancer genome is characterized by the accumulation of multiple mutations and alterations that ultimately result in the deregulation of various cell-signaling pathways. Knowledge of these genetic alterations has provided a unique opportunity to develop therapies targeted against these pathways and to identify which patients are likely to benefit from them. The progress that has been made in identifying genomic biomarkers that can predict response to antileukemic therapies is highlighted. Global gene expression profiling approaches utilizing tipifarnib in acute myeloid leukemia as an in-depth example are focused on. The challenges in developing associated theranostic molecular assays are discussed. The integration of validated genomic-based assays with common morphological tests may allow for improved prediction of antileukemic drug response.